Feature Type | Standardized |
Nominal ANOVA |
||||
---|---|---|---|---|---|---|
mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.03 |
mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.03 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |
mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.03 |
mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.33 | 0.04 |
mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.065 | 0.04 |
mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.04 |
mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |